Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Update

Pyxis Oncology, Inc. (NASDAQ:PYXS) was the target of a large growth in short interest in January. As of January 15th, there was short interest totaling 2,307,831 shares, a growth of 33.1% from the December 31st total of 1,733,403 shares. Currently, 4.1% of the company’s stock are short sold. Based on an average trading volume of 1,930,381 shares, the days-to-cover ratio is currently 1.2 days. Based on an average trading volume of 1,930,381 shares, the days-to-cover ratio is currently 1.2 days. Currently, 4.1% of the company’s stock are short sold.

Pyxis Oncology Trading Down 7.1%

Shares of NASDAQ:PYXS opened at $1.45 on Monday. The company has a market cap of $90.28 million, a price-to-earnings ratio of -0.91 and a beta of 1.45. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.55. The company has a 50-day moving average price of $2.56 and a 200 day moving average price of $2.45.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. As a group, equities analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after acquiring an additional 14,566 shares during the period. Bank of America Corp DE raised its position in Pyxis Oncology by 2,690.9% during the third quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after acquiring an additional 593,853 shares during the period. Longaeva Partners L.P. purchased a new position in shares of Pyxis Oncology in the third quarter valued at approximately $1,117,000. Citadel Advisors LLC purchased a new position in shares of Pyxis Oncology in the third quarter worth about $749,000. Finally, Jane Street Group LLC purchased a new position in Pyxis Oncology during the second quarter worth approximately $370,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Guggenheim increased their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Zacks Research lowered shares of Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Royal Bank Of Canada cut their price objective on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, January 25th. Finally, HC Wainwright raised their target price on Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average price target of $7.20.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.